Navigation Links
Novel export-inhibitor shows promise for treating CLL
Date:12/12/2011

An experimental drug that works by blocking the export of key control molecules from the nucleus of cancer cells shows promise as a treatment for chronic lymphocytic leukemia (CLL) and other incurable B-cell malignancies, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

The agent, called KPT-SINE, belongs to a new class of drugs called selective inhibitors of nuclear export (SINE). The agent was developed by Karyopharm Therapeutics Inc. It is designed to kill cancer cells by restoring biochemical pathways that normally cause unhealthy cells to self-destruct through a process called programmed cell death, or apoptosis.

The agent targets a protein called CRM1, which, until now, has not been adequately explored in CLL, the researchers say. During disease progression, cancer cells use CRM1 to shunt certain apoptosis-related proteins out of the nucleus, thereby avoiding cell death.

"We believe that KPT-SINE and other nuclear-export inhibitors may represent a unique, entirely new therapeutic strategy for treating cancer by simultaneously restoring multiple normal cell death pathways," says OSUCCC James research scientist Dr. Rosa Lapalombella who is a co-investigator on the study with Dr. John Byrd, director of the division of hematology and co-director of the OSUCCC James CLL Experimental Therapeutics Laboratory at OSUCCC James.

The researchers hypothesize that KPT-SINE will inhibit CRM1 and keep these regulatory proteins in the nucleus where they can initiate programmed cell death.

Lapalombella will discuss the role of CRM1 inhibition in the treatment of CLL on Monday, December 12, at 7:00 a.m. during the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

The study, which used CLL cells from patients and a mouse model of CLL, provides essential proof-of-concept data to design and initiate phase I clinical testing of KPT-SINE in patients with these incurable diseases, Lapalombella notes.

"We are excited by our preliminary findings that KPT-SINE represents a promising targeted therapy for CLL patients," Byrd says. "We look forward to transitioning our research toward early clinical development in patients with CLL and related diseases, based upon the data generated by our team."
'/>"/>

Contact: Eileen Scahill
Eileen.Scahill@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Novel experimental agent is highly active in CLL patients, interim study shows
2. Researchers identify a novel therapeutic approach for liver cancer
3. Novel drug wipes out deadliest malaria parasite through starvation
4. Novel approach to treating breast cancer shows great promise
5. Wayne State receives $1.9 million from NIH to create novel cystic fibrosis treatments
6. Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial
7. Wayne State University to study novel treatment for antibiotic-resistant bacteria
8. Novel, noninvasive measurement a strong predictor for heart failure in general population
9. UK HealthCare surgeons are first to perform novel procedures prior to transplant
10. Novel approach to treat proliferative vitreoretinopathy shows promise
11. Novel strategy stymies SARS et al.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The ... and inspirational speaker Jan Fox will serve as keynote speaker at the organization’s ... participants with tools to more effectively communicate with their own organizational staff and ...
(Date:2/10/2016)... West Palm Beach, Florida (PRWEB) , ... February ... ... Golf & Country Club) announced that it has been awarded the prestigious Distinguished ... of the World award program conducted by BoardRoom magazine, one of the most ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week announced the ... monitor mounts ever. , “Our goal was to develop a product from the ... that we have ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. ...
(Date:2/10/2016)... ... 2016 , ... A new leadership team for Mid-South Youth Camp, operated by ... the announcement Monday night, Feb. 8, prior to the evening session of the university’s ... creator of GO! Camp, has been named director. Gayle McDonald, currently the assistant director ...
(Date:2/10/2016)... (PRWEB) , ... February 09, 2016 , ... ... sports concussion, yet the cause of injury may be one of many possible ... advanced PT Continuing Education Course , Mastering Rehab Solutions for the ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... PUNE, India , February 10, 2016 ... to a new market research report "Pharmaceutical Packaging Equipment ... Packaging, Wrapping, Labeling & Serialization), by Product Type (Tablet, ... to 2020", published by MarketsandMarkets, studies the global market during ... is expected to grow at a CAGR of 6.9% ...
(Date:2/10/2016)... February 10, 2016 ... Targeted Therapeutics and Companion Diagnostic Market to 2019 ... and Environment" research report indicates that the core ... billion by 2020 growing at a CAGR of ... diagnostics and targeted therapeutics and is dominated by ...
(Date:2/9/2016)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, today announced financial ... half of fiscal year 2016 ended December 31, ... --> Highlights for the second quarter and ...
Breaking Medicine Technology: